|[April 05, 2012]
Research and Markets: Germany Pharmaceuticals and Healthcare Report Q2 2012 - In 2011, Germany's Drug Market Was the Fourth Largest Globally After the US, Japan and China
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/9d484527/germany_pharmaceut)
has announced the addition of the "Germany
Pharmaceuticals and Healthcare Report Q2 2012" report to their
Despite the threat of austerity measures and the government's focus on
cost-containment within the pharmaceuticals and healthcare sector, as
well as the impact of generic competition as a result of the patent
cliff, BMI expect Germany to remain attractive to innovative drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: EUR39.39bn (US$55.15bn) in 2011 to EUR38.40bn
(US$51.46bn) in 2012; -2.5% decline in local currency terms and 6.7% in
US dollar terms.
- Halthcare: EUR275.10bn (US$385.15bn) in 2011 to EUR280.97bn
(US$376.49bn) in 2012; 2.1% growth in local currency terms and -2.2% in
US dollar terms.
- Medical devices: EUR14.97bn (US$22.96bn) in 2011 to EUR15.64bn
(US$20.95bn) in 2012; 4.5% growth in local currency terms and no growth
in US dollar terms. Forecasts unchanged from Q411.
Key Trends And Developments
- In December 2011, positive news for multinational drugmaker
AstraZeneca, the company's Brilique (ticagrelor) for patients with acute
coronary syndromes (ACS (News - Alert)) has passed Germany's new cost-benefit
assessment. Ticagrelor is the first reversibly binding oral P2Y12
adenosine diphosphate receptor antagonist and the first in a new class
of drugs, cyclo-pentyl-triazolo-pyrimidines (CPTPs), which are
chemically distinct from thienopyridines such as BMS/Sanofi's Plavix
(clopidogrel) and Eli Lilly/Daiichi Sankyo's Effient (prasugrel).
- In January 2012, in negative news for multinational drugmakers Eli
Lilly and Boehringer Ingelheim, Trajenta (linagliptin) for patients with
type 2 diabetes did not pass the Institute for Quality and Efficiency in
Healthcare (IQWiG)'s assessment (a part of the
Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) cost-benefit assessment).
- Bayer HealthCare
- Boehringer Ingelheim
- Stada Arzneimittel
- Merck KGaA
- GlaxoSmithKline (GSK)
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/9d484527/germany_pharmaceut
[ Back To SIP Trunking Home's Homepage ]